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Abstract
Background: Congenital adrenal hyperplasia (CAH) due to steroid 11β-hydroxylase deficiency (11β-OHD) is a rare
form of CAH associated with low renin hypertension, hypokalemia, hyperandrogenemia and ambiguous genitalia in
affected females. Herein we describe the clinical, hormonal and molecular characteristics of two Uzbekistan siblings
with 11β-OHD and analyze the effects of a splicing mutation.
Case presentation: A 46,XX girl presented with genital ambiguity and low renin hypertension; her 46,XY brother
presented with precocious puberty. Hormonal studies suggested 11β-OHD. Mutation analysis was performed by PCR
followed by Sanger sequencing of the entire coding regions and their flanking introns of the CYP11B1 gene. Mutation
analysis showed that both patients were compound heterozygous for IVS7 + 1G > A, and c.421C > T. Although the
identified mutations have been previously described, this is, to our knowledge, the first report of these mutations in
compound heterozygotes. A minigene assay was used to determine the effects of the splicing mutation. The constructs
containing either the wild-type or the splice-site mutant CYP11B1 genomic DNA of exons-introns 6–9 were transfected
into COS-7 cells; subsequently, RNA splicing was assessed by reversed transcribed-PCR of CYP11B1 complementary DNA.
The minigene assay revealed that the IVS7 + 1G > A mutation resulted in two shorter incorrectly spliced products; one
skipping the exon 7 and the other skipping the exons 7–8. The c.421C > T mutation leads to the introduction of a
premature stop codon at residue 141 (p.R141X). These mutations are expected to code non-functional proteins.
Conclusion: Compound heterozygous mutations (IVS7 + 1G > A and p.R141X) in the CYP11B1 gene were found to cause
11β-OHD. The IVS7 + 1G > A mutation causes aberrant splicing of CYP11B1 leading to exon skipping. This finding could
facilitate the future novel therapies targeted on splicing modulation to treat human disease.
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Background
11β-hydroxylase deficiency (11β-OHD) caused by muta-
tions in the CYP11B1 gene accounts for approximately
5–8 % of congenital adrenal hyperplasia (CAH) in non-
consanguineous populations, but accounts for ~15 % of
cases in both Muslim and Jewish Middle Eastern popula-
tions [1]. Steroid 11β-hydroxylase (P450c11β, CYP11B1)
converts 11-deoxycortisol to cortisol, representing the final
step in cortisol biosynthesis, and 11-deoxycorticosterone
(DOC) to corticosterone. Thus, deficient P450c11β activity
results in impaired cortisol synthesis and accumulation of
11-deoxycortisol and the mineralocorticoid precursor
DOC, which leads to significant hypertension, a hallmark
feature of this CAH variant [1]. Accumulated steroid pre-
cursors are shunted into the androgen synthesis pathway,
leading to androgen excess. Classic 11β-OHD results in
virilization of the external genitalia in affected females
(46,XX disorders of sex development) as well as precocious
puberty, accelerated growth and bone maturation in both
sexes. Patients with 11β-OHD can have elevated concentra-
tions of 17-hydroxyprogesterone (17OHP), which accumu-
lates two steps behind the enzymatic block, so that 11β-
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OHD may be detected by 17OHP newborn screening pro-
gram [2]. The diagnosis is established by elevated basal
concentrations of DOC and 11-deoxycortisol, which hyper
respond to ACTH stimulation.
CYP11B1 is located on the long arm of chromosome 8
(8q21), consisting of 9 exons, and encodes 503 amino acids.
To date, over 80 mutations in CYP11B1 gene are described.
Most are missense and nonsense mutations, but splice-site
mutations, small or gross deletions/insertions, and complex
rearrangements with CYP11B2 have also been identified
[3–5]. The majority of CYP11B1 mutations are associated
with classic 11β-OHD, and only a few mutations causing
non-classic 11β-OHD which can manifest later in otherwise
asymptomatic women with hirsutism, and menstrual ir-
regularities [6, 7].
In this report, we describe two siblings with the clin-
ical and hormonal phenotypes of 11β-OHD and identi-
fied compound heterozygous mutations in the CYP11B1
gene. The splicing mutation was studied in vitro for its
functional consequences with a minigene experiment
and showed exon-skipping which confirmed the clinical
diagnosis.
Case presentation
The patients were siblings from a non-consanguineous
Uzbekistan family. Patient 1 was a 3-yr-old 46,XX female
with ambiguous genitalia. She was previously evaluated for
her abnormal genital development and underwent first geni-
tal surgery in Turkey. On an initial evaluation at age 2 y
8 m, her height was 100 cm (+2.1 SD), her weight was
15.8 kg, (+1.4 SD), blood pressure (BP) was 110/70 mmHg
(94th/96th percentiles). The physical examination revealed
that the phallus was 5 cm long and 2 cm wide (Prader grade
IV); no gonads were palpable in the inguinal region. The
areola and palmar creases were pigmented bilaterally. An
ACTH stimulation test (250 μg) showed grossly elevated
baseline ACTH (238 pg/mL) and basal cortisol of 4.7 μg/dL
with non-response to ACTH and moderately elevated
progesterone and 17OHP after 60 min; 11-deoxycortisol
and androstenedione concentrations were markedly high
(Table 1). The serum sodium was 136 mmol/L, potassium
3.1 mmol/L, plasma renin activity (PRA) was very low at
15 ng/dL/h (nl, 171–1115), and aldosterone 2 ng/dL (nl,
3–35). Her total testosterone levels were 132 ng/dL (nl,
<3–10) and dehydroepiandrosterone sulfate (DHEAS)
165.2 μg/dL (nl, <5-57). She was followed up at the King
Chulalongkorn Memorial Hospital (Bangkok, Thailand)
due to the family relocation at age 3 yr for further man-
agement. After receiving the results of an ACTH stimula-
tion test, she was started treatment with hydrocortisone,
5 mg thrice daily (10 mg/m2/d) which improved BP into
the normal range (90/60 mmHg), suppressed testosterone,
and PRA became measurable (200–496 ng/dL/h).
Patient 2 is the younger brother of Patient 1. He pre-
sented at 2 years of age with acne and masculinization
(isosexual precocious puberty). Physical examination re-
vealed an advanced maturation of external genitalia as
well as a low-pitched voice. His Tanner stages were G3
and PH1, and each of his testes was 3 mL in volume.
His height was 97 cm (+3.2 SD) and weight was 17 kg
(+2.9 SD). Height gain was accelerated from 12-month-
old on the growth chart (from +2.6 SD to +3.2 SD). Skin
pigmentation appeared consistent with his ethnicity, but
no evident mucosal pigmentation. His BP was 110/
65 mmHg (92th/95th percentiles). Labs revealed serum
Na 136 mmol/L, K 4.3 mmol/L, bicarbonate 24 mmol/L,
BUN 12 and Cr 0.3 mg/dL, respectively. An ACTH
stimulation test showed elevated baseline ACTH, a low
basal cortisol (2.3 μg/dL) with non-response to ACTH
and moderately elevated 17OHP after 60 min (Table 1).
11-deoxycortisol concentrations were not measured.
PRA was low at 106 ng/dL/h (nl, 171–1115), and low al-
dosterone 0.2 ng/dL (nl, 3–35). He was then treated with
hydrocortisone 2.5 mg thrice daily (11 mg/m2/d). His
blood pressure was well controlled, and PRA was in-
creased up to 738 ng/dL/h.
DNA sequencing
Genomic DNA from peripheral blood leucocytes of the
patients and their parents was extracted by using the
QIAamp® DNA Blood Mini Kit (Qiagen, Valencia, CA)
after taking informed consent. The coding sequence of
Table 1 Basal and 60 min post ACTH (250 μg) stimulated adrenal steroid profile
Steroids Patient 1 Patient 2 Reference values
(age 2 y 8 m) (age 2 y)
Basal Stimulated Basal Stimulated Basal Stimulated
ACTH (pg/mL) 238 - 150 - 10–65 -
Cortisol (μg/dL) 4.72 4.65 2.3 2.3 3–22 27–50
17-OHP (ng/dL) 2880 2730 1310 2380 13–173 85–250
Progesterone (ng/dL) 464 499 - - a a
Androstenedione (ng/dL) 2750 2710 - - <10-48 <10–87
11-deoxycortisol (ng/dL) 15100 - - - 7-210 95–323
aNote: Reference values are unavailable
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CYP11B1 gene including exon-intron boundaries was amp-
lified in eight fragments using specific primers (Table 2).
PCR products were treated with ExoSAP-IT (USP Corpor-
ation, Cleveland, OH), and sent for direct sequencing at
Macrogen Inc. (Seoul, Korea). Analyses were performed by
Sequencher 4.2 (Gene Codes Corporation, Ann Arbor, MI).
Minigene construction and splicing analysis
We performed a minigene in vitro experiment of the
CYP11B1 splicing mutation. A segment of the wild-type
(WT) and mutant (IVS7 + 1G >A) genomic DNA (gDNA)
of CYP11B1 gene consisting of exons 6 to 9 and their in-
between introns was amplified by PCR using the oligonu-
cleotides listed in Table 2. We used the gDNA of a normal
control and the patient with IVS7 + 1G >A CYP11B1 mu-
tation as a template of minigene constructs. PCR reactions
were carried out in a 20 μl volume containing 50 ng
gDNA, 10xPCR buffer, 25 mM MgCl2, 10 μM dNTPs, 5
U/μl Taq polymerase and 10 μM of each primer, using the
following parameters: 30s at 94 °C, 30s at 60 °C and
1.30 min at 72 °C. The PCR product was cleaved with
BamHI-HF and XbaI enzymes and cloned into the corre-
sponding sites of pcDNA™3.1/myc-His B mammalian
expression vector (Invitrogen, Carlsbad, CA) using T4
DNA ligase (New England BioLabs, UK). The wild-type
and mutant vectors were confirmed by direct sequencing
using NCBI Reference Sequences (RefSeq) NG_007954.1
as the genomic reference and NM_000497.3 as the mRNA
reference.
COS-7 cells were cultured in Dulbecco’s Modified Eagles
Medium, High Glucose (HyClone Laboratories, Logan,
UT) supplemented with 10 % fetal bovine serum (Sigma-
Aldrich, Singapore) and 0.01 % penicillin/streptomycin
(HyClone Laboratories) at 37 °C in a humidified 5 % CO2
incubator. Cells were grown on 6-well plates and transiently
transfected with the wild-type and mutant minigene
constructs (1 μg) using Effectene® Transfection Reagent
(Qiagen). Cells incubated for 48 h after transfection
and then were washed 3 times with PBS and kept fro-
zen at − 20 °C. Total cellular RNA was extracted using
QIAamp® RNA Blood Mini Kit (Qiagen) and treated
with DNaseI (Qiagen). The RNAs were then used as
template for cDNA synthesis using ImProm-II™ Reverse
Transcription System (Promega Corporation, Madison,
WI). Finally, both the WT and mutant cDNAs were
amplified by PCR using the same primers and condi-
tions as used for the minigene construction. The PCR
products were analyzed by electrophoresis on a 1 %
agarose gel followed by staining with ethidium bromide.
Each PCR product was confirmed by Sanger sequencing
after subcloning into pGEM®-T Easy vectors (Promega).
Results
Mutation analysis
DNA sequencing of the entire coding regions and their
flanking introns of the CYP11B1 gene showed that both
siblings were compound heterozygous for a nonsense muta-
tion c.421C >T in its exon 3 (NCBI RefSeq NG_007954.1),
causing the introduction of a premature stop codon at resi-
due 141 (p.R141X); and a splice site mutation, c.1200 +
1G>A which is at the 5’ donor splice site of the intron 7
(IVS7 + 1G>A). These identified mutations were reported
previously [8–10], but their pathogenic mechanisms have
not clearly been elucidated. Sequence analysis of the paren-
tal gDNA demonstrated that the mother was heterozygous
for the c.421C >T mutation and the father, heterozygous for
the c.1200 + 1G>A mutation (Fig. 1).
Minigene analysis of the splice site mutation
We hypothesized that the c.1200 + 1G>A (IVS7 + 1G>A)
mutation located at the splicing donor site of intron 7 would
create an abnormal splicing of the mRNA. To examine this
possibility, we constructed expression vectors containing the
WT and the mutant c.1200 + 1G>A CYP11B1 minigene
sequence from exons 6 to 9 (Fig. 2a). The resultant mini-
genes were transfected into COS-7 cells. Then, total RNA
was isolated and analyzed by the RT-PCR method. We
found that the mutant c.1200 + 1G>A CYP11B1 minigene
was processed to two major incorrectly spliced products
which were shorter than the WT minigene (Fig. 2b). Se-
quence analysis of the RT-PCR products after subcloning
into pGEM®-T Easy vector revealed that one of the mutant
Table 2 Sequences of oligonucleotide primers used for PCR amplification and minigene construction
Primer Sense Strand Antisense Strand
CYP11B1_Exon 1 5’- GTTCTCCCATGACGTGATCCCTCT – 3’ 5’- TCCAAAGGATGCAGAGTGCC – 3’
CYP11B1_Exon 2 5’ – TGGACAGGAGACACTTTGGAT – 3’ 5’ – TCGCCGCTTACAGCAAGAAC – 3’
CYP11B1_Exon 3–4 5’ – TGGGGACAAGGAGGATGGGATAC – 3’ 5’ – TGGTGGAGAGGGAGAAATTGGG – 3’
CYP11B1_Exon 4 5’ – CGTGGGAAGATCCAGCCTCAG – 3’ 5’ – GGAAGGTGAGGAATCCCCGAC – 3’
CYP11B1_Exon 5 5’ – AGGAGGAGGACACTGAAGGATG – 3’ 5’ – AGGCAGGCTTGGCATCACC – 3’




5’ – AGAGAGCACAGGAAGCCCCATC – 3’
5’ – GTTCCCCCTTCAGCATAATCTC – 3’
5’ - AGTCGGATCCCTTGCTGATGACGCTCTTTG - 3’
5’ – CAGTCCCACATTGCTCAAGC – 3’
5’ – GCCCTCGGGAGTTCCATTT – 3’
5’- GTACTCTAGAATGGCTCTGAAGGTGAGGAG - 3’
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fragments skipped the entire exon 7, while containing the
full-length sequences of exons 6, 8, 9. The other mutant
PCR product skipped the exons 7 and 8, while retaining
full-length sequences of exons 6 and 9 (Fig. 2c).
Discussion
In this study, we have described two severe CYP11B1muta-
tions found in two siblings diagnosed with classic 11β-
OHD in a family from Uzbekistan. Virilization and hyper-
tension are the main clinical features of the classic 11β-
OHD. Despite inability of aldosterone synthesis, overpro-
duction of DOC, which is a less potent mineralocorticoid,
causes salt retention and hypertension. However, affected
newborns may have mild, transient salt loss presumably
due to relatively high mineralocorticoids resistance in the
newborn period [11]. Signs of mineralocorticoid excess
generally correlate poorly with the degree of virilization in
affected girls [3]. Blood pressure is usually normal during
infancy and hypertension is often identified later in toddler-
hood or in childhood, although its presence in infancy was
demonstrated [12].
Most of the CYP11B1 mutations described to date
result in the classic form of 11β-OHD. Unlike 21-
hydroxylase deficiency, molecular-genetic studies of 11β-
OHD are relatively fewer, and a number of identified
CYP11B1 mutations have not been functionally charac-
terized [5, 13]. Therefore, the exact genotype-phenotype
prediction of 11β-OHD has not been well established.
Previous studies showed that in vitro activities less than
5 % were considered severe and consistent with classic
11β-OHD [5, 13]. In this present study, we describe two
siblings suffering from classic 11β-OHD who were com-
pound heterozygous for a nonsense and a splice-site
CYP11B1 mutations. The nonsense p. R141X is expected
c.1200+1G>A/WT WT/c.421C>T (p.R141X)  
Control
Mutant
c.1200+1G>A c.421C>T (p.R141X)  
a
b
Fig. 1 Mutation analysis by direct DNA sequencing. a Family tree. The arrow indicates our proband. Both siblings carried compound
heterozygous mutations; the point mutation at position bp 421 (c.421C > T) leads to the substitution of arginine to stop at amino acid position
141 (p.R141X), and the base change from G to A at the first position in intron 7 (c.1200 + 1G > A or IVS7 + 1G > A). The father is heterozygous for
the c.1200 + 1G > A mutation and the mother is heterozygous for p.R141X. b Electropherograms of the patient and a healthy control
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to lead to a premature stop in the exon 3 and yields a
truncated enzyme lacking the essential residues for heme
binding domain, consistent with our patients’ clinical phe-
notypes and near-completely abolished in vitro CYP11B1
activity in a recent study [14].
In addition, we identified a previously described IVS7 +
1G >A mutation in CYP11B1 affecting the consensus slice
donor site of the exon 7. The minigene experiment con-
firmed that this splice site mutation caused exon skipping
(either a complete loss of the exon 7 or both exons 7 and
8). Most reported CYP11B1 mutations are located in exons
6, 7, and 8 and 70 % of amino acid sequences in these
exons are identical in human, ox, rat, and mouse, suggest-
ing that exons 6–8 are essential for the enzymatic activity
of CYP11B1 [15]. Recently, Nguyen et al. [9] studied a
minigene experiment of this same mutation. Nonetheless,
the authors designed a shorter minigene construct which
had only exon 7, intron 7, and exon 8. They found that the
IVS7 + 1G >A mutation caused an intron retention.
Splicing errors are well recognized causes of genetic
diseases. Previous data point to an estimated frequency of
sequence variations affect pre-mRNA splicing up to 50 %
of the alleles causing human disease [16, 17]. Splice site nu-
cleotide substitutions may result in skipping of the involved
exon, intron retention, creation of a pseudo-exon within
intron, usage of a cryptic splice site, or a combination of
several of these [18, 19]. Hence, the design of minigene
constructs is important to correctly identify the splicing ef-
fect of specific splice site mutations. Recent data have
suggested that cassette exon skipping is the most common
alternative splicing event in humans [19, 20]. To date, a
+1G >A substitution at the 5’-splice donor site has been
identified in a number of human diseases [21]. Functional
studies of other +1G >A 5’-splice site mutations have
shown either recognition of a 5’-cryptic splice site or exon
skipping [22]. Therefore, we have designed the minigene
constructs including exons 6–9 and introns 6–8 and our
results confirmed that the IVS7 + 1G >A mutant construct
results in exon skipping. To date, the therapies to modulate
RNA mis-splicing using antisense oligonucleotide or small
molecules are emerging [19]. The understanding of definite
genetic mechanism could expand opportunities for gene
therapy. Modulation of aberrant splicing transcripts can be-
come a novel therapeutic approach for many diseases
caused by splice site defects.
Conclusions
In summary, we describe two compound heterozygous
CYP11B1 mutations that severely affect normal protein
structure explaining a severe phenotype of classic 11β-
hydroxylase deficiency. Our findings suggest the mutation
IVS7 + 1G >A causes aberrant splicing of CYP11B1 leading
to exon skipping. Our findings may help for better under-
standing of splice site mutation mechanism and facilitate
the future new therapies targeted on splicing modulation to
treat human disease.
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